Status:
UNKNOWN
Silymarin in COVID-19 Pneumonia
Lead Sponsor:
Cairo University
Conditions:
COVID-19
Viral Pneumonia Human Coronavirus
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
A randomized placebo controlled trial to assess the clinical outcome in COVID-19 Pneumonia following administration of Silymarin owing to its role as a p38 MAPK pathway inhibitor and its antiviral, an...
Detailed Description
To date, there are no drugs or other therapeutics approved by the U.S. Food and Drug Administration (FDA) to prevent or treat COVID-19 that has spread globally resulting in the ongoing pandemic as dec...
Eligibility Criteria
Inclusion
- COVID-19 patients with CT Chest-proven viral pneumonia with any degree of severity.
Exclusion
- Patients \< 18 years of age.
- Patients with mild symptoms (as per WHO criteria) of SARS-CoV-2
Key Trial Info
Start Date :
August 16 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 28 2021
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04394208
Start Date
August 16 2020
End Date
February 28 2021
Last Update
August 18 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cairo University
Giza, Cairo Governorate, Egypt, 12613